Caris Life Sciences (CAI) Preferred Dividend Payments (2024 - 2025)
Caris Life Sciences (CAI) posted quarterly Preferred Dividend Payments of $61.0 million for Q2 2025, up 149.25% quarter-over-quarter from $24.5 million in Q1 2025.
Powered by 
Analysis
Caris Life Sciences (CAI) Preferred Dividend Payments (2024 - 2025) Analysis & Trends
Caris Life Sciences' Preferred Dividend Payments history runs 2 years deep, the most recent figure standing at $61.0 million for Q2 2025.
- In Q2 2025, Preferred Dividend Payments changed N/A year-over-year to $61.0 million; the TTM figure through Mar 2026 stood at $61.0 million (down 49.54% YoY), while the FY2025 annual figure was $85.4 million, down 11.35% from the prior year.
- Preferred Dividend Payments for Q2 2025 stood at $61.0 million, up from $24.5 million in the prior quarter.
- The five-year high for Preferred Dividend Payments was $96.4 million in Q4 2024, with the low at $24.5 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Caris Life Sciences | 7.08 Bn | 6.28 Bn | 182.38 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 384.44 Mn |
| Mar 31, 2025 | 24.46 Mn |
| Dec 31, 2024 | 25.00 Mn |
| Sep 30, 2024 | 24.66 Mn |
| Jun 30, 2024 | 23.59 Mn |